


IN RE: Application of Trevor Charles ROCHE

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Serial No.:	To be assigned	Art Unit:	7 ° *
Filing Date:	Concurrently herewith	Examiner:	
For: Dr	y Powder Compositions		
P.O. Box 14	ner for Patents 450 , VA 22313-1450		
	INFORMATION DISCLO	SURE STATEME	NT
Applicants r Examiner ar	request that the references identified on Form PTC and officially made of record in accordance with the	0-1449 appended hereto e provisions of 37 CFR	be considered by the 1.97
[ ] Co [X] A c Int	pies of the references listed on the attached form lipies of the references were submitted in parent appropriate opposed in the International Search Report which issuance PCT/GB03/01542 is submitted he ernational Search Report are listed on the attached plicants understand that copies have been supplied.	plication Serial No ned on International App rewith. All of the public I form PTO-1449 as iten	
A. [X]	The Information Disclosure Statement subn filing date of the above application or date of application or before the mailing date of a foccurs last. 37 CFR 1.97(b).	of entry into the national	stage of an international
[]	The Information Disclosure Statement su of a first office action after the filing of a C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).		
В. []	The Information Disclosure Statement transmitted filing date of the above application or the date of an international application or after the mailing devent occurred last, but <b>before</b> the mailing date  (1) a final action under § 1.113 or  (2) a notice of allowance under § 1.311, whichever occurs first.	of entry into the national date of the first Office A	stage as set forth in § 1.491 of
[]	Applicant hereby certifies that each item of informal statement was cited in a communication from a application not more than three months prior to	foreign patent office in a	counterpart foreign
[]	Applicant elects the option to pay the fee set for Disclosure Statement under § 1.97(c) (\$180.00).		submission of an Information



C. [] The Information Disclosure Statement transmitted herewith is being filed after a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.

In accordance with the requirements of 37 CFR 1.97(d):

- Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. [or]
- Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [ ] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.
- [X] Please charge any required fees to Deposit Account No.07-1392.

[ ] A duplicate copy of this paper is attached.

Respectfully Submitted,

James P. Riek

Attorney of Record: Registration No. 39,009

Date: October 12, 2004
GlaxoSmithKline
Corporate Intellectual Property
5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-8022 Facsimile: (919) 483-7988

DT04 Por'd PCT/PT0 1 2 OCT 2004

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT					ATTORNEY DOCKET NO. PG4713USW APPLICANT Trevor Charles ROCHE		SERNL SER 1104		
					FILING DATE			GROUP	
					Concurrently herewith			GROOT	
			U.S. F	PATENT D	OCUMENTS				
Examiner Initials		Patent Number	Issue Date		Name	Class	Subclass	Filing Date If Appropriate	
	1.	4,353,365	10/12/1982	HALLWO	ORTH et al.				
	2.	4,668,218	05/26/1987	VIRTANEN					
	3.	4,811,731	03/14/1989	NEWELL et al.					
	4.	5,035,237	07/30/1991	NEWELL et al.					
	5.	5,590,645	01/07/1997	DAVIES et al.					
	6.	5,873,360	02/23/1999	DAVIES	et al.				
	<u> </u>					<del>                                     </del>			
				ontinue on p	Dage ΓDOCUMENT	'S			
		Document	Publication					Translation	
		Number	Date		Country	Class	Subclass	Yes   No	
	7.	EP 0416951 B1	01/12/1994	EPO				X	
	8.	WO 99/33853	07/08/1999	WIPO					
	9.	WO 00/28979	05/25/2000	WIPO				X (Abstract)	
	10.	WO 00/38811	07/06/2000	WIPO				X	
	11.	WO 01/32125	05/10/2001	WIPO				X	
	12.	WO 02/15876	02/28/2002	WIPO					
	13.	WO 02/43750	06/06/2002	WIPO					
	14.	WO 02/066422	08/29/2002	WIPO				X	
<del> </del>	15.	WO 02/070490	09/12/2002	WIPO				X	
	16.	WO 02/076922	10/03/2002	WIPO				X (Abstract)	
· · · · · · · · · · · · · · · · · · ·		OTHER BOOK		ontinue on j					
·	T	OTHER DOCUM	AENTS (Includi	ng Author,	Title, Journal-l	Date, Page Num	ber, Etc.)		
	<del>                                     </del>	_		-					
							····		
,									
			-						
	-								
							<del></del>		
				<del></del>			·		
EXAMINER Continue					DATE CONSIDERED		PD .		
	•					DATE	CONGIDERE		
		al if citation conside							
citation if no	ot in co	nformance and not o	considered. Inclu	ide copy of	this form with ne	ext communication	on to the appl	icant.	